Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 3/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982252 | 0.84 | MAP2K1 (0.37) | MAPK13MAPK12MAPK11MAPK14DAO | |
| SCHEMBL19050666 | 0.82 | KDM4E (0.38) | MAPK13MAPK12MAPK11MAPK14HSD17B10 | |
| SCHEMBL12540303 | 0.81 | RXFP1 (0.36) | MAPK13MAPK12MAPK11MAPK14HSD17B10 | |
| SCHEMBL388455 | 0.69 | MAPK13 (0.34) | MAPK13MAPK12MAPK11MAPK14DAO | |
| SCHEMBL684564 | 0.69 | MAPK13 (0.39) | MAPK13MAPK12MAPK11MAPK14DAO | |
| Hydrochloric Acid SCHEMBL23152525 | 0.68 | MPO (0.37) | DAOKDM4EALDH1A1GAA | |
| SCHEMBL19050790 | 0.67 | MAPK13 (0.39) | MAPK13MAPK12MAPK11MAPK14DAO | |
| SCHEMBL12694976 | 0.64 | MAPK13 (0.31) | MAPK13MAPK12MAPK11MAPK14DAO | |
| SCHEMBL1991827 | 0.64 | GRIN2D (0.40) | MAPK13MAPK12MAPK11MAPK14PKM | |
| SCHEMBL12540185 | 0.63 | RXFP1 (0.35) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES (US) | 2014-12-25 | — | — | US | disclosed |
| US-8829052-B2 | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8808742-B2 | Compositions and methods for preparing and using same | ARDEA BIOSCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-1912636-B1 | N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8648116-B2 | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | ARDEA BIOSCIENCES, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120022076-A1 | DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK | MADERNA ANDREAS (US) | 2012-01-26 | — | — | US | disclosed |
| US-8101799-B2 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | ARDEA BIOSCIENCES, INC (US) | 2011-02-10 | — | — | US | disclosed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | BRAF, MAPK1, MAPK12 | MAPK13 28/4885MAPK12 3/4885MAPK11 46/4885 |
| US-20120022076-A1 | DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAPK13 37/4885MAPK12 31/4885MAPK11 43/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAPK13 37/4885MAPK12 31/4885MAPK11 43/4885 |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAPK13 37/4885MAPK12 31/4885MAPK11 43/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | MAPK13 22/4885MAPK12 11/4885MAPK11 45/4885 |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | NRAS, BRAF, MAP3K2 | MAPK13 61/4885MAPK12 39/4885MAPK11 57/4885 |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | HMGCR, PCSK9, C5 | MAPK13 4648/4885MAPK12 4485/4885MAPK11 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.